I was adding in a little bit of context to explain why people should care about iPSCs - even if they are not used as therapies. Mainly because the last paragraph in GP comment focused on the dearth of direct clinical applications.

My point is that iPSCs are still quite useful in pharmaceutical research and development - a therapy adjacent area.

Improved cell models are still a pretty big deal. Part of the reason for high costs and failure rates in pharma R&D is that experimental models we use to generate data are imperfect. Better models = better data = better decisions.